It is reasonable to assume that even with GCGR mutations in β cells, glucagon binding to GLP-1R exerts an insulin-promoting effect that can reduce blood glucose concentrations in patients with diabetes. The gene discussed is GLP1R; the disease is diabetes mellitus.